Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
NewsExtended efgartigimod treatment shows lasting gains in ocular MG. Phase 3 data from the ADAPT OCULUS trial show that patients with ocular myasthenia gravis who received additional cycles of subcutaneous efgartigimod (Vyvgart) beyond the placebo-controlled period continued to see symptom improvement. Benefits were seen across both antibody-positive and triple-seronegative patient groups, as measured by patient-reported ocular MGII scores.
Extended efgartigimod treatment keeps delivering for ocular MG patients
New phase 3 data from the ADAPT OCULUS trial, presented at the 2026 AANEM Annual Meeting, show that patients with ocular myasthenia gravis (MG) who received additional cycles of subcutaneous efgartigimod (Vyvgart) beyond the initial placebo-controlled period continued to experience meaningful symptom improvement. The study enrolled both acetylcholine receptor antibody-positive (AChR+) and triple-seronegative adults, tracking outcomes using the patient-reported Myasthenia Gravis Impairment Index (MGII) ocular score.
Importantly, the findings suggest the benefits of treatment don't plateau after the first round — patients kept improving with more cycles. That said, the data don't yet define the optimal number of cycles or guarantee progressive improvement for every individual patient. It's also worth noting that ocular MG remains an unapproved indication; Vyvgart is currently approved only for generalized MG and CIDP.
By the Numbers
Why it matters: For neurologists managing ocular MG — a condition with limited approved therapies — these findings suggest that sustained efgartigimod use could offer durable, deepening benefits, potentially shaping future treatment strategies if regulatory approval follows.
